

ASX ANNOUNCEMENT

13 January 2026

Correction to Director interest notices



Little Green Pharma Ltd (ASX:LGP) ("**LGP**" or the "**Company**") wishes to advise of the following matters in relation to the attached Appendix 3X Initial Director's Interest Notice and Appendix 3Y Change in Director's Interest Notice for Director, Mr Paul Long:

- Mr Long was appointed as a Director of the Company on 1 March 2025. An Appendix 3X – Initial Directors Interest Notice ("**Appendix 3X**") was released to ASX on 4 March 2025.
- Subsequent to the Appendix 3X, an Appendix 3Y – Change in Director's Interest Notice ("**Appendix 3Y**") for Mr Long was released to ASX on 1 September 2025.
- The Company notes that within the foregoing Appendix 3X and the Appendix 3Y, due to administrative oversight it did not disclose Mr Long's indirect ownership of 351,111 ordinary shares through PFL Green Growth Pty Ltd of which Mr Long is the sole shareholder and beneficiary.
- The Company confirms that Mr Long has not purchased, sold or transferred any of the shares held by PFL Green Growth Pty Ltd since the date of his appointment as a Director of the Company on 1 March 2025.
- As a result of the above points, the Company wishes to correct Mr Long's Appendix 3X and Appendix 3Y by including the ordinary shares held by him under PFL Green Growth Pty Ltd.
- All other disclosures on the Appendix 3X and Appendix 3Y are correct.

ENDS

BY ORDER OF THE BOARD



Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Managing Director
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint

To easily update your communication preferences, visit: www.investorcentre.com/au



Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Long
Date of appointment	1 March 2025

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
<u>Direct interest:</u>
499,769 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
<u>Indirect Interest:</u>	
As beneficiary of the Long Family Trust	1,926,191 ordinary shares 500,000 ordinary shares (escrowed until 30 June 2025) 2,000,000 options expiring 31 July 2027 500,000 performance rights class F expiring 17/08/2026 500,000 performance rights class G expiring 17/08/2026 500,000 performance rights class H expiring 17/08/2026 500,000 performance rights class I expiring 27/02/2028 500,000 performance rights class J expiring 27/02/2028 500,000 performance rights class K expiring 27/02/2028 1,000,000 retention share rights vesting 31/03/2026
PFL Green Growth Pty Ltd <i>Mr Long is the sole shareholder and beneficiary</i>	351,111 ordinary shares

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Little Green Pharma Ltd
ACN 615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Long
Date of last notice	4 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Paul Frederick Long <The Long A/C> Mr Long is a beneficiary PFL Green Growth Pty Ltd Mr Long is the sole shareholder and beneficiary
Date of change	1 September 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	Direct 499,769 ordinary shares Paul Frederick Long <The Long A/C> 1,926,191 ordinary shares 500,000 ordinary shares (escrowed until 31/03/2026) 2,000,000 options exercisable at \$0.138 expiring 31/07/2027 500,000 performance rights class F expiring 17/08/2026 500,000 performance rights class G expiring 17/08/2026 500,000 performance rights class H expiring 17/08/2026 500,000 performance rights class I expiring 27/02/2028 500,000 performance rights class J expiring 27/02/2028 500,000 performance rights class K expiring 27/02/2028 1,000,000 retention share rights vesting 31/03/2026 PFL Green Growth Pty Ltd 351,111 ordinary shares
Class	Options exercisable at \$0.1725 expiring 31/07/2028
Number acquired	2,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil. Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21/08/2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Direct 499,769 ordinary shares</p> <p>Paul Frederick Long <The Long A/C> 1,926,191 ordinary shares</p> <p>500,000 ordinary shares (escrowed until 31 March 2026)</p> <p>2,000,000 options exercisable at \$0.138 expiring 31 Jul 2027</p> <p>2,000,000 options exercisable at \$0.1725 expiring 31/07/2028</p> <p>500,000 performance rights class F expiring 17/08/2026</p> <p>500,000 performance rights class G expiring 17/08/2026</p> <p>500,000 performance rights class H expiring 17/08/2026</p> <p>500,000 performance rights class I expiring 27/02/2028</p> <p>500,000 performance rights class J expiring 27/02/2028</p> <p>500,000 performance rights class K expiring 27/02/2028</p> <p>1,000,000 retention share rights vesting 31/03/2026</p> <p>PFL Green Growth Pty Ltd 351,111 ordinary shares</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21/08/2025</p>

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.